New drug M701 aims to stop Cancer-Related fluid buildup without drains
NCT ID NCT06266091
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve survival. 115 participants were enrolled in this Phase 2 trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M701
What this could lead to
If successful, this could provide a new way to control malignant ascites, reducing the need for repeated drainage procedures and improving quality of life.
What could go wrong
This is a Phase 2 trial with only 115 participants, so results may not be definitive. The drug may not work better than standard drainage, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100141, China